Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroid Effect on Achalasia Variant Esophagogastric Junction Outflow Obstruction
NCT06588348Phase 1Active, not recruiting
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jul 2022
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prednisone in esophagogastric junction outflow obstruction (EGJOO), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Response in esophageal motility to study intervention at 14 days. Started Jul 2022; status: active, not recruiting.
02
Drugs
prednisone
03
Conditions
esophagogastric junction outflow obstruction (EGJOO)
Beyond the preview
Go deeper on NCT06588348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588348.